These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7706012)

  • 1. Screening for colorectal cancer: what are the costs?
    Weller D; Moss J; Hiller J; Thomas D; Edwards J
    Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial.
    Whynes DK
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):155-65. PubMed ID: 10612015
    [No Abstract]   [Full Text] [Related]  

  • 3. [Health economics analysis of colorectal screening].
    Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
    Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimates of costs and effects of screening for colorectal cancer in the United States.
    Byers T; Gorsky R
    Cancer; 1992 Sep; 70(5 Suppl):1288-95. PubMed ID: 1387342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for colorectal cancer: which test can we afford?
    Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for colorectal cancer: too early to be dogmatic.
    Solomon MJ
    Med J Aust; 1996 Jul; 165(2):68-9. PubMed ID: 8692061
    [No Abstract]   [Full Text] [Related]  

  • 9. Mathematical models and cost-effective screening strategies for colorectal cancer.
    Smith RA
    CMAJ; 2010 Sep; 182(12):1283-4. PubMed ID: 20713572
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests.
    Heresbach D; Chauvin P; Grolier J; Josselin JM
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1372-9. PubMed ID: 20802341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Colorectal cancer screening is profitable].
    Pikkarainen P
    Duodecim; 1999; 115(17):1813-4. PubMed ID: 11941648
    [No Abstract]   [Full Text] [Related]  

  • 12. Costs of screening for colorectal cancer: an Australian programme.
    Gow J
    Health Econ; 1999 Sep; 8(6):531-40. PubMed ID: 10544318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing cancer: using health dollars wisely.
    Wasserman S
    NCSL Legisbrief; 2004 Feb; 12(8):1-2. PubMed ID: 14974484
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of colorectal cancer screening in the elderly.
    Wagner JL; Herdman RC; Wadhwa S
    Ann Intern Med; 1991 Nov; 115(10):807-17. PubMed ID: 1929029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.
    Wu GH; Wang YM; Yen AM; Wong JM; Lai HC; Warwick J; Chen TH
    BMC Cancer; 2006 May; 6():136. PubMed ID: 16723013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal cancer screening: methods, benefits and costs.
    Kronborg O; Wahrendorf J
    Eur J Cancer; 1994; 30A(6):877-9. PubMed ID: 7917551
    [No Abstract]   [Full Text] [Related]  

  • 19. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia.
    Pignone MP; Flitcroft KL; Howard K; Trevena LJ; Salkeld GP; St John DJ
    Med J Aust; 2011 Feb; 194(4):180-5. PubMed ID: 21401458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Screening for colorectal cancer: a cost benefit analysis on a health prevention programme at the Boehringer Ingelheim Company].
    Schneider M; Häck HJ
    Dtsch Med Wochenschr; 2011 May; 136(20):1047-52. PubMed ID: 21560104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.